SEOUL, South Korea — September 3, 2025 — Leads & Copy — MicrobiotiX, a biotechnology company focused on bacteriophage-based therapeutics, announced the completion of an extended Series B investment round, securing a total of 20 billion KRW.
The cumulative investment in MicrobiotiX across all rounds has reached 29 billion KRW. Following an initial 15 billion KRW secured in October 2024, the round concluded with an additional 5 billion KRW from new investors, including Paratus Investment, Pureun Investment, and OTIUM CAPITAL.
MicrobiotiX specializes in phage therapy targeting diseases caused by multidrug-resistant bacteria. The company’s platform includes a phage library, an in silico module, and a cGMP-grade phage manufacturing facility.
MicrobiotiX was selected for the Korean Ministry of Health and Welfare’s “Infectious Disease Prevention and Treatment Technology Development Project,” receiving 2.5 billion KRW to support the first human clinical trial of phage therapy in Korea.
CEO Dongeun Yong stated that the investment and government project selection will establish MicrobiotiX and Korea as leaders in phage therapy, addressing the global health crisis of antibiotic-resistant bacterial infections and enhancing the competitiveness of the Korean bio-industry.
Contact: bd@microbiotix.net
Source: MicrobiotiX
